Skip to content
Disclosery

Ghost Tree Capital, LLC

Follow

13F filer, CIK 1595851, NEW YORK, NY

Ghost Tree Capital, LLC reported $302,919,910 across 57 holdings for the quarter ended 2023-06-30, in a 13F-HR filed 2023-08-14. Its ten largest share positions make up 51.48% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001420506-23-001536

Period
2023-06-30
Reported value
$303M
Holdings
57
Top 10 weight
51.48%
New
15
Sold out
16

Largest buys vs the previous quarter

SecurityShares changeApprox. value
REVANCE THERAPEUTICS INCadded+275,000$6.96M
MLTXadded+135,000$6.88M
MDGLadded+25,000$5.78M
ONCnew+22,500$4.01M
AKROadded+85,000$3.97M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CTI BIOPHARMA CORPexited-2,000,000-$8.4M
AXSMreduced-115,000-$8.26M
PFEexited-200,000-$8.16M
JNJexited-50,000-$7.75M
TGTXreduced-275,000-$6.83M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2023

Share positions as resolved from 13F-HR 0001420506-23-001536, largest first. % of portfolio is the value over $277,094,110, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
TGTXTG THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,100,000 shares; 2023Q2: 825,000 shares 825,000$20.5M7.4%-275,000Timeline
MLTXMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 195,000 shares; 2023Q2: 330,000 shares 330,000$16.8M6.07%+135,000Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 85,000 shares; 2023Q1: 275,000 shares; 2023Q2: 360,000 shares 360,000$16.8M6.07%+85,000Timeline
APLSAPELLIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 164,620 shares; 2023Q2: 180,000 shares 180,000$16.4M5.92%+15,380Timeline
PCVXVAXCYTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 160,000 shares; 2023Q1: 225,000 shares; 2023Q2: 280,000 shares 280,000$14M5.05%+55,000Timeline
REVANCE THERAPEUTICS INCREVANCE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 250,000 shares; 2023Q2: 525,000 shares 525,000$13.3M4.8%+275,000
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 20,000 shares; 2023Q1: 30,000 shares; 2023Q2: 55,000 shares 55,000$12.7M4.59%+25,000Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 350,000 shares; 2023Q1: 475,000 shares; 2023Q2: 550,000 shares 550,000$11.9M4.28%+75,000Timeline
VKTXVIKING THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 300,000 shares; 2023Q1: 600,000 shares; 2023Q2: 650,000 shares 650,000$10.5M3.8%+50,000Timeline
SRPTSAREPTA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 55,000 shares; 2023Q1: 60,000 shares; 2023Q2: 85,000 shares 85,000$9.73M3.51%+25,000Timeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 130,000 shares; 2023Q1: 110,000 shares; 2023Q2: 100,000 shares 100,000$8.93M3.22%-10,000Timeline
REATA PHARMACEUTICALS INCREATA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 500,000 shares; 2023Q1: 70,000 shares; 2023Q2: 85,000 shares 85,000$8.67M3.13%+15,000
AXSMAXSOME THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 235,000 shares; 2023Q1: 225,000 shares; 2023Q2: 110,000 shares 110,000$7.9M2.85%-115,000Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 150,000 shares; 2023Q1: 325,000 shares; 2023Q2: 350,000 shares 350,000$7.33M2.64%+25,000Timeline
MIRATI THERAPEUTICS INCMIRATI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 200,000 shares; 2023Q1: 140,000 shares; 2023Q2: 200,000 shares 200,000$7.23M2.61%+60,000
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 200,000 shares; 2023Q2: 185,000 shares 185,000$7.12M2.57%-15,000Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 800,000 shares; 2023Q1: 550,000 shares; 2023Q2: 575,000 shares 575,000$6.81M2.46%+25,000Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 225,000 shares; 2023Q2: 225,000 shares 225,000$6.21M2.24%0Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 165,000 shares; 2023Q1: 175,000 shares; 2023Q2: 240,000 shares 240,000$5.71M2.06%+65,000Timeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 120,000 shares; 2023Q2: 190,000 shares 190,000$4.17M1.51%+70,000Timeline
INCYINCYTE CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 75,000 shares; 2023Q2: 65,000 shares 65,000$4.05M1.46%-10,000Timeline
ONCBEONE MEDICINES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 22,500 shares 22,500$4.01M1.45%newTimeline
AMBRX BIOPHARMA, INC. SPONS…AMBRX BIOPHARMA, INC. SPONSORED A…Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 250,000 shares; 2023Q2: 238,225 shares 238,225$3.92M1.42%-11,775
VIRVIR BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 150,000 shares 150,000$3.68M1.33%newTimeline
ALPINE IMMUNE SCIENCES INCALPINE IMMUNE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 200,000 shares; 2023Q2: 347,432 shares 347,432$3.57M1.29%+147,432
AEROVATE THERAPEUTICS INCAEROVATE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 135,000 shares; 2023Q1: 200,000 shares; 2023Q2: 201,197 shares 201,197$3.45M1.25%+1,197
ZNTLZENTALIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 100,000 shares 100,000$2.82M1.02%newTimeline
KARUNA THERAPEUTICS INCKARUNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 40,000 shares; 2023Q1: 17,500 shares; 2023Q2: 12,500 shares 12,500$2.71M0.98%-5,000
TARSTARSUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 80,000 shares; 2023Q1: 80,000 shares; 2023Q2: 150,000 shares 150,000$2.71M0.98%+70,000Timeline
FOLDAMICUS THERAPEUTICQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 475,000 shares; 2023Q2: 200,000 shares 200,000$2.51M0.91%-275,000Timeline
ASTRIA THERAPEUTICS INCASTRIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 450,000 shares; 2023Q1: 450,000 shares; 2023Q2: 300,173 shares 300,173$2.5M0.9%-149,827
QUREUNIQURE NVQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 375,000 shares; 2023Q2: 215,000 shares 215,000$2.46M0.89%-160,000Timeline
KRYSKRYSTAL BIOTECH INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 20,000 shares 20,000$2.35M0.85%newTimeline
VERONA PHARMA PLCVERONA PHARMA PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 110,000 shares 110,000$2.33M0.84%new
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 154,250 shares 154,250$2.21M0.8%newTimeline
FUSION PHARMACEUTICALS INCFUSION PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 350,000 shares; 2023Q2: 412,699 shares 412,699$1.93M0.7%+62,699
IMMUNOGEN INCIMMUNOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 124,977 shares; 2023Q2: 100,000 shares 100,000$1.89M0.68%-24,977
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 280,981 shares 280,981$1.76M0.63%newTimeline
WHWKWHITEHAWK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 90,000 shares; 2023Q1: 150,000 shares; 2023Q2: 250,000 shares 250,000$1.71M0.62%+100,000Timeline
RCUSARCUS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 75,000 shares; 2023Q2: 75,000 shares 75,000$1.52M0.55%0Timeline
RCKTROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 75,000 shares 75,000$1.49M0.54%newTimeline
BCRXBIOCRYST PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 225,000 shares; 2023Q1: 275,000 shares; 2023Q2: 200,000 shares 200,000$1.41M0.51%-75,000Timeline
MORPHIC HLDG INCMORPHIC HLDG INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 20,000 shares 20,000$1.15M0.41%new
INHIBRX INCINHIBRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 35,000 shares 35,000$909K0.33%new
SPRINGWORKS THERAPEUTICS INCSPRINGWORKS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 27,578 shares; 2023Q2: 27,578 shares 27,578$723K0.26%0
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 25,000 shares; 2023Q2: 42,000 shares 42,000$722K0.26%+17,000Timeline
RNAMAVIDITY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 100,000 shares; 2023Q1: 125,000 shares; 2023Q2: 65,000 shares 65,000$721K0.26%-60,000Timeline
IOVAIOVANCE BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,300,000 shares; 2023Q1: 1,000,000 shares; 2023Q2: 100,000 shares 100,000$704K0.25%-900,000Timeline
PTCTPTC THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 16,675 shares 16,675$678K0.24%newTimeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 64,000 shares 64,000$645K0.23%newTimeline
RAIN ONCOLOGY INCRAIN ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 250,000 shares; 2023Q2: 325,000 shares 325,000$390K0.14%+75,000
REPLREPLIMUNE GROUP INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 10,865 shares 10,865$252K0.09%newTimeline
VNDAVANDA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 12,500 shares; 2023Q2: 31,000 shares 31,000$204K0.07%+18,500Timeline
Mersana Therapeutics IncMersana Therapeutics IncQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: not reported; 2023Q2: 61,250 shares 61,250$202K0.07%new
FIBROGEN INCFIBROGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q3: restricted; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 26,500 shares; 2023Q2: 36,500 shares 36,500$98.5K0.04%+10,000

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
XBISPDR SERIES TRUST S&P BIOTECHcall300,000$25M0
BIOXCEL THERAPEUTICS INCBIOXCEL THERAPEUTICS INC COMcall130,000$866Knew

Sold out in Q2 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REATA PHARMACEUTICALS INCREATA PHARMACEUTICALS INC300,000$27.3Mcall
SRPTSAREPTA THERAPEUTICS INC125,000$17.2Mcall
CTI BIOPHARMA CORPCTI BIOPHARMA CORP2,000,000$8.4Mshares
PFEPFIZER INC200,000$8.16Mshares
JNJJOHNSON & JOHNSON50,000$7.75Mshares
IVERIC BIO INCIVERIC BIO INC175,000$4.26Mshares
ACRSACLARIS THERAPEUTICS INC425,000$3.44Mshares
APLSAPELLIS PHARMACEUTICALS INC51,900$3.42Mcall
89BIO INC89BIO INC200,000$3.05Mshares
IRONDISC MEDICINE INC100,000$2.12Mshares
ALTALTIMMUNE INC400,000$1.69Mcall
PROMETHEUS BIOSCIENCES INCPROMETHEUS BIOSCIENCES INC15,000$1.61Mshares
89BIO INC89BIO INC100,000$1.52Mcall
GERNGERON CORP450,000$977Kshares
X4 Pharmaceuticals, Inc.X4 Pharmaceuticals, Inc.850,000$740Kshares
KEZAR LIFE SCIENCES INCKEZAR LIFE SCIENCES INC175,000$548Kshares

How Q2 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-23-001536 base2023-08-14acceptance time not in the bulk data set